Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05162976
Title CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center

Hodgkin's lymphoma


Azacitidine + Nivolumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.